

ORAL PRESENTATION

Open Access

# O223. Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children

C Zhang<sup>1\*</sup>, P Denti<sup>1</sup>, USH Simonsson<sup>2</sup>, G Maartens<sup>1</sup>, MO Karlsson<sup>2</sup>, H McIlleron<sup>1</sup>

From Tenth International Congress on Drug Therapy in HIV Infection  
Glasgow, UK. 7-11 November 2010

## Objectives

Children with HIV associated tuberculosis often require co-formulated lopinavir/ritonavir (LPV/RTV)-based anti-retroviral treatment with rifampicin-based antitubercular treatment (ATT). Rifampicin (RIF), a potent inducer of drug-metabolizing systems, profoundly reduces the bioavailability of LPV. The aims of this study were to develop an integrated population pharmacokinetic (PK) model describing LPV and RTV PK in children with and without concomitant ATT using two different dosing approaches and to estimate doses of LPV/RTV achieving target exposures during ATT in young children.

## Methods

A population PK analysis was conducted in NONMEM. During ATT 15 children were given LPV with extra RTV (LPV/RTV ratio 1:1) and 20 children were given twice the usual dose of LPV/RTV (ratio 4:1) 12 hourly; 39 children without tuberculosis and 11 children undergoing repeated sampling after ATT were treated with standard 12 hourly doses of LPV/RTV (median LPV dose 11.6 mg/kg). Goodness-of-fit plots and visual predictive checks were used to evaluate the models.

## Results

In a one-compartment model with first-order absorption to describe LPV PK, and a one-compartment model with transit absorption for RTV, the dynamic influence of RTV concentration on the clearance of LPV was

modelled as direct inhibition with an Emax model. Allometric scaling for weight was used for clearance and volume of both LPV and RTV. During ATT, the relative oral bioavailability of LPV was reduced by 79% in children receiving twice the usual dose of LPV/RTV. The clearance of RTV was 18 L/h with, and 13 L/h without, ATT. The baseline clearance of LPV, when RTV was undetected, estimated 4.34 L/h. With increasing concentrations of RTV, clearance of LPV decreased in a sigmoid relationship (EC<sub>50</sub> 0.051 mg/L). Volume of distribution for LPV and RTV were 11.7 and 102 L, respectively. Simulations predicted that children weighing 4-6, 6-8, 8-12 and 12-18 kg need respective doses of 65, 50, 37 and 30 mg/kg LPV/RTV (4:1) 8 hourly in order to maintain LPV concentrations > 1 mg/L in at least 95% of children.

## Conclusions

The model describes the drug-drug interaction between LPV, RTV and RIF. Using 8 hourly doses, approximately 2.5 to 5.5 times the standard doses are required to maintain therapeutic LPV concentrations in young children during ATT.

## Author details

<sup>1</sup>University of Cape Town, Cape Town, South Africa. <sup>2</sup>University of Uppsala, Uppsala, Sweden.

Published: 8 November 2010

## References

1. La Porte CJL, Colberes EPH, Bertz R, et al: Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampicin in healthy volunteers. *Antimicrob Agents Chemother* 2004, **48**:1553-1560.

<sup>1</sup>University of Cape Town, Cape Town, South Africa  
Full list of author information is available at the end of the article

2. Natella R, John van den A, Aline B, *et al.*: Population pharmacokinetics of lopinavir predict suboptimal therapeutic concentrations in treatment-experienced human immunodeficiency virus-infected children. *Antimicrob Agents Chemother* 2009, **53**:2532-2538.

doi:10.1186/1758-2652-13-S4-O24

**Cite this article as:** Zhang *et al.*: O223. Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children. *Journal of the International AIDS Society* 2010 **13**(Suppl 4):O24.

**Submit your next manuscript to BioMed Central  
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

